Athira Pharma, Inc. Stock Price, News & Analysis

Athira Pharma (NASDAQ: ATHA) reported its financial results for 2021 and provided a clinical update on its Alzheimer's disease programs. As of December 31, 2021, the company had $319.7 million in cash, up from $268.2 million the previous year. R&D expenses increased to $42.8 million, while G&A expenses rose to $21.2 million, reflecting expanded operations. Athira is set to report topline data from its Phase 2 ACT-AD study in Q2 2022 and aims to complete enrollment in the LIFT-AD Phase 3 study by Q3 2022. The company remains optimistic about its clinical pipeline and potential for shareholder value.

Athira Pharma has appointed Michael A. Panzara, M.D., MPH, a seasoned expert in CNS drug development, to its Board of Directors. With over 20 years in the biopharmaceutical industry, Panzara's experience includes pivotal roles at Wave Life Sciences, Sanofi Genzyme, and Biogen. Panzara's leadership in neurology drug development positions him to enhance Athira's clinical programs, especially for Alzheimer's and Parkinson's diseases. CEO Mark Litton highlighted Panzara's insights as critical in advancing therapies aimed at improving neurological health.

Athira Pharma (NASDAQ: ATHA) announced participation in two major investor conferences. The first is the Stifel 2022 Virtual CNS Days on March 28-29 at 2:30 PM ET, featuring a fireside chat with key executives including Dr. Mark Litton and Dr. Hans Moebius. The second event is the 21st Annual Needham Virtual Healthcare Conference from April 11-14, with a presentation scheduled for April 14 at 3:00 PM ET. Live webcasts will be available on the Athira website, with recordings accessible for 30 days after.

Athira Pharma (NASDAQ: ATHA) announced the presentation of baseline data from its fully enrolled Phase 2 ACT-AD clinical trial for its lead candidate, fosgonimeton (ATH-1017), targeting mild-to-moderate Alzheimer’s disease. The trial included 77 participants, averaging 71.4 years old, with 57 completing the study. Preliminary results are set for release in Q2 2022. These findings will inform the ongoing Phase 3 LIFT-AD study. Fosgonimeton aims to enhance neuronal health and cognitive function through its mechanism involving hepatocyte growth factor.

Athira Pharma, a late clinical-stage biopharmaceutical company, announced it will report its financial results for Q4 and full year 2021 on March 24, 2022. The conference call to discuss these results will start at 4:30 PM ET. Athira focuses on developing small molecules to enhance neuronal health and combat neurodegeneration, with its lead candidate, fosgonimeton (ATH-1017), targeting Alzheimer’s and Parkinson’s diseases. For more details, visit their website.

Athira Pharma (NASDAQ: ATHA) announced an update on its fully enrolled ACT-AD Phase 2 clinical trial for fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer's disease. The trial has enrolled 77 subjects across the US and Australia, focusing on cognitive and functional measures. Presentation details include a session at the AD/PD 2022 congress in Barcelona on March 20, 2022. Fosgonimeton aims to restore neuronal health and slow neurodegeneration. The primary endpoint is Event-Related-Potential (ERP) P300 Latency.

Athira Pharma (NASDAQ: ATHA) announced promising preclinical data for its compounds, fosgonimeton and ATH-1020, targeting neurodegenerative and neuropsychiatric disorders. Fosgonimeton enhances the HGF/MET system, showing neurotrophic and procognitive effects in Alzheimer's and Parkinson's models. ATH-1020 demonstrated significant reductions in depression-like behaviors and normalized sensory deficits in schizophrenia models. Ongoing clinical trials, including Phase 2 and Phase 3 studies for Alzheimer’s, are underway, with expectations for future results to further validate these findings.

Athira Pharma (NASDAQ: ATHA) announced the first presentation of preclinical data for its candidate ATH-1020, designed to enhance the hepatocyte growth factor (HGF)/MET system for neuropsychiatric conditions. This data will be presented at the ASENT Annual Meeting from February 28 to March 3, 2022. ATH-1020 aims to address depression-like behaviors and improve cognitive function. The Phase 1 study in healthy volunteers is set to begin in Q1 2022. The company’s lead candidate, fosgonimeton, is also in trials for Alzheimer’s and related diseases.

Athira Pharma announced positive results from a Phase 1 clinical trial of fosgonimeton (ATH-1017) in Alzheimer’s patients. The trial demonstrated a statistically significant improvement in Event-Related Potential (ERP) P300 latency, indicating potential procognitive properties. Fosgonimeton showed a positive safety and tolerability profile across all dosages. The drug has been named by the World Health Organization, enhancing its recognition. Upcoming data from the Phase 2 ACT-AD trial are expected in Q2 2022, showcasing ongoing commitment to developing treatments in neurology.